Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer

This publication has 10 references indexed in Scilit:

• Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer
  Journal of Clinical Oncology, 2001
• Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer
  Journal of Clinical Oncology, 2001
• Cancer Statistics, 2001
  CA: A Cancer Journal for Clinicians, 2001
• Eastern Cooperative Oncology Group Phase I Trial of Protracted Venous Infusion Fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients With Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity
  Journal of Clinical Oncology, 2000
• Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic Cancer
  Journal of Clinical Oncology, 1999
• Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors
  Annals of Oncology, 1998
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
  Journal of Clinical Oncology, 1997
• Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group
  Cancer, 1981